← Oncology Approval Tracker

FDA DECISION ·

Libtayo

cemiplimab-rwlc · Regeneron

Accelerated approvalNew or expanded indicationBasal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Apr 28, 2023

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Patients with metastatic basal cell carcinoma after a hedgehog pathway inhibitor, or when that treatment was inappropriate.

LAMPGEN ANALYSIS

Why it matters

The metastatic indication entered through accelerated approval. FDA granted traditional approval on April 28, 2023.

What research teams should watch

Record metastatic status and keep the 2021 pathway distinct from the later conversion.

PRIMARY RECORDS

Sources